Ultragenyx

Yahoo Finance • 4 days ago

Barclays Remains Cautious on Ultragenyx (RARE), Cites Setrusumab Study Analysis Despite 70% Positive Result Outlook

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the most promising stocks with huge upside potential. On November 24, Barclays analyst Gena Wang lowered the firm’s price target on Ultragenyx (RARE) to $50 from $81 and maintained an... Full story

Yahoo Finance • 8 days ago

Ultragenyx to Participate in Investor Conferences in December

NOVATO, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic dise... Full story

Yahoo Finance • 11 days ago

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today repo... Full story

Yahoo Finance • 27 days ago

Ultragenyx outlines 14%–20% 2025 revenue growth, advances late-stage pipeline with $400M OMERS financing

Earnings Call Insights: Ultragenyx Pharmaceutical Inc. (RARE) Q3 2025 MANAGEMENT VIEW * CEO Emil Kakkis indicated that Ultragenyx is at a “defining moment” with four commercial products showing consistent double-digit annual revenue gr... Full story

Yahoo Finance • 28 days ago

Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $400 Million to OMERS Life Sciences

Bolsters balance sheet with non-dilutive capital at an attractive cost Beginning in January 2028 OMERS will receive an additional 25% of the North American Crysvita® royalty interest capped at 1.55 times the purchase price Proceeds to fu... Full story

Yahoo Finance • last month

Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update

NOVATO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic disea... Full story

Yahoo Finance • last month

Globant slips even as Wells Fargo starts with Equal-Weight rating

[Globant glass building with blue sky in the background] Arturo Rosenow * Globant (NYSE:GLOB [https://seekingalpha.com/symbol/GLOB]) shares slipped 0.7% on Wednesday, even as Wells Fargo started coverage on the technology company with a... Full story

Yahoo Finance • 2 months ago

ClearBridge Small Cap Strategy adds KWR, RNA, exits SEAT, GDRX among Q3 moves

The ClearBridge Small Cap Strategy underperformed its Russell 2000 Index benchmark during the third quarter, despite registering gains in 10 of the 11 sectors in which it was invested during the quarter. ClearBridge Small Cap Strategy, in... Full story

Yahoo Finance • 2 months ago

Credo rebounds after plans to develop custom silicon for AI data centers

[Shot of Data Center With Multiple Rows of Fully Operational Server Racks. Modern Telecommunications, Artificial Intelligence,server room,3d rendering] Oselote Credo (NASDAQ:CRDO [https://seekingalpha.com/symbol/CRDO]) stock price rebound... Full story

Yahoo Finance • 2 months ago

Ultragenyx annuncia l'approvazione da parte dell'AIFA (Agenzia Italiana del Farmaco) del rimborso di Evkeeza® (evinacumab) per i pazienti pediatrici di età pari a 6 mesi con ipercolesterolemia familiare omozigote (HoFH)

MILANO, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), azienda biofarmaceutica focalizzata sullo sviluppo e la commercializzazione di nuove terapie per malattie genetiche rare e ultra-rare, ha annunciato... Full story

Yahoo Finance • 2 months ago

Assenagon Boosts Ultragenyx Pharmaceutical Inc. (RARE) Stake by 439% Amid Breakthrough Pipeline

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is among the most promising biotech stocks to buy according to hedge funds. According to a recent disclosure with the SEC, Assenagon Asset Management S.A. lifted its holdings in Ultragenyx Pharm... Full story

Yahoo Finance • 2 months ago

Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President

NOVATO, Calif., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced the appointment of Eric Olson as chief business officer (CBO) and executive vice president effective September 22, 2025, fo... Full story

Yahoo Finance • 2 months ago

Regeneron nabs FDA label expansion for Ultragenyx-partnered cholesterol drug

[FDA Approved Products or Drugs] Olivier Le Moal Regeneron Pharmaceuticals (NASDAQ:REGN [https://seekingalpha.com/symbol/REGN]) announced on Friday that the U.S. FDA approved a label expansion for its anti-cholesterol agent Evkeeza, marke... Full story

Yahoo Finance • 3 months ago

Is Ultragenyx Pharmaceutical (RARE) a Compelling Long-Term Opportunity?

Sands Capital, an investment management company, released its “Sands Capital Select Growth Strategy” Q2 2025 investor letter. A copy of the letter can be downloaded here.  U.S. large-cap growth equities recovered from a sharp sell-off in e... Full story

Yahoo Finance • 3 months ago

Ultragenyx releases long-term phase 3 data on gene therapy for metabolic disorder

[Rare disease. health problem. woman doctor showing words written on a tablet.] * Ultragenyx Pharmaceutical (NASDAQ:RARE [https://seekingalpha.com/symbol/RARE]) said that week 96 phase 3 data of its gene therapy DTX401 for glycogen stor... Full story

Yahoo Finance • 3 months ago

Ultragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)

At Week 96 participants experienced even greater reductions in daily cornstarch intake while maintaining low levels of hypoglycemia, improved levels of euglycemia and improved fasting tolerance Phase 3 results are further supported by ear... Full story

Yahoo Finance • 3 months ago

Ultragenyx to Participate at Investor Conferences in September

NOVATO, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic dise... Full story

Yahoo Finance • 3 months ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

NEW YORK, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE).  Such investors are advised to contact Danielle Pe... Full story

Yahoo Finance • 3 months ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE).  Such investors are advised to contact Danielle Pe... Full story

Yahoo Finance • 4 months ago

Ultragenyx earnings beat by $0.13, revenue topped estimates

Investing.com - Ultragenyx (NASDAQ: RARE) reported second quarter EPS of $-1.17, $0.13 better than the analyst estimate of $-1.30. Revenue for the quarter came in at $166.5M versus the consensus estimate of $161.97M. Ultragenyx’s stock... Full story